Print Page     Close Window     

Investor Home

Corporate Profile

BeiGene is a commercial-stage biopharmaceutical company rooted in China that is dedicated to becoming a global leader in the discovery, development and commercialization of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer.

We have three internally-developed late-stage clinical drug candidates:

  • Zanubrutinib (BGB-3111) — an investig...more >
Stock Quotemore >
BGNE (American Depositary Shares)

$193.20

0.00 (0.00%)

05/21/18  4:00 p.m. ET

Currency is USD
Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent Press Releasesmore >
BeiGene Initiates Phase 3 Trial of Pamiparib as Maintenance Therapy in Chinese Patients with Ovarian Cancer - May 17, 2018
BEIJING, China and CAMBRIDGE, Mass., May 17, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage ... Read More
BeiGene to Present at the 2018 UBS Global Healthcare Conference - May 15, 2018
CAMBRIDGE, Mass. and BEIJING, China, May 15, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage ... Read More

E-mail Alerts

Sign up to receive e-mail alerts
 

© 2016 BeiGene. All Rights Reserved.